Morepen Laboratories Share Price
Sector: Biotechnology & Drugs
62.76 +0.45 (0.72%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
62.40
Today’s High
64.00
52 Week Low
41.66
52 Week High
100.80
62.76 +0.45 (0.72%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
62.50
Today’s High
64.05
52 Week Low
42.00
52 Week High
100.90
Key Metrics
- Market Cap (In Cr) 3438.96
- Beta 0.68
- Div. Yield (%) 0.32
- P/B 2.95
- TTM P/E 21.75
- Peg Ratio 7.09
- Sector P/E 22.67
- D/E 0
- Open Price 62.41
- Prev Close 62.31
Morepen Laboratories Analysis
Price Analysis
-
1 Week3.57%
-
3 Months28.34%
-
6 Month-19.34%
-
YTD-20.28%
-
1 Year12.21%
Risk Meter
- 55% Low risk
- 55% Moderate risk
- 55% Balanced Risk
- 55% High risk
- 55% Extreme risk
Morepen Laboratories News
Stocks to buy under ₹100: Experts recommend six shares to buy today
2 min read . 22 May 2025Stocks to buy under ₹100: Experts recommend three shares to buy today
2 min read . 15 May 2025Stocks to buy under ₹100: Experts recommend three shares to buy on Friday
2 min read . 28 Mar 2025Morepen Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 1811.58
- Selling/ General/ Admin Expenses Total
- 354.79
- Depreciation/ Amortization
- 28.98
- Other Operating Expenses Total
- 123.41
- Total Operating Expense
- 1666.49
- Operating Income
- 145.09
- Net Income Before Taxes
- 155.11
- Net Income
- 118.02
- Diluted Normalized EPS
- 2.2
- Period
- 2025
- Total Assets
- 1778.1
- Total Liabilities
- 621.87
- Total Equity
- 1156.23
- Tangible Book Valueper Share Common Eq
- 18.43
- Period
- 2025
- Cashfrom Operating Activities
- 32.06
- Cashfrom Investing Activities
- -321.51
- Cashfrom Financing Activities
- 299.89
- Net Changein Cash
- 10.44
- Period
- 2024
- Total Revenue
- 1690.43
- Selling/ General/ Admin Expenses Total
- 301.51
- Depreciation/ Amortization
- 33.47
- Other Operating Expenses Total
- 141.58
- Total Operating Expense
- 1565.28
- Operating Income
- 125.16
- Net Income Before Taxes
- 135.42
- Net Income
- 96.16
- Diluted Normalized EPS
- 1.88
- Period
- 2024
- Total Assets
- 1293.21
- Total Liabilities
- 445.98
- Total Equity
- 847.23
- Tangible Book Valueper Share Common Eq
- 14.73
- Period
- 2024
- Cashfrom Operating Activities
- 73.37
- Cashfrom Investing Activities
- -83.3
- Cashfrom Financing Activities
- 5.2
- Net Changein Cash
- -4.72
- Period
- 2023
- Total Revenue
- 1417.53
- Selling/ General/ Admin Expenses Total
- 293.7
- Depreciation/ Amortization
- 27.93
- Other Operating Expenses Total
- 70.86
- Total Operating Expense
- 1365.93
- Operating Income
- 51.6
- Net Income Before Taxes
- 55.76
- Net Income
- 38.68
- Diluted Normalized EPS
- 0.77
- Period
- 2023
- Total Assets
- 1110.5
- Total Liabilities
- 357.59
- Total Equity
- 752.91
- Tangible Book Valueper Share Common Eq
- 12.77
- Period
- 2023
- Cashfrom Operating Activities
- -91.17
- Cashfrom Investing Activities
- -46.51
- Cashfrom Financing Activities
- 143.54
- Net Changein Cash
- 5.86
- Period
- 2022
- Total Revenue
- 1546.83
- Selling/ General/ Admin Expenses Total
- 271.95
- Depreciation/ Amortization
- 27.64
- Other Operating Expenses Total
- 74.26
- Total Operating Expense
- 1437.8
- Operating Income
- 109.03
- Net Income Before Taxes
- 126.7
- Net Income
- 101.68
- Diluted Normalized EPS
- 1.96
- Period
- 2022
- Total Assets
- 1070.05
- Total Liabilities
- 491.49
- Total Equity
- 578.56
- Tangible Book Valueper Share Common Eq
- 9.91
- Period
- 2022
- Cashfrom Operating Activities
- -57.76
- Cashfrom Investing Activities
- -31.68
- Cashfrom Financing Activities
- 63.85
- Net Changein Cash
- -25.58
- Period
- 2021
- Total Revenue
- 1188.06
- Selling/ General/ Admin Expenses Total
- 225.24
- Depreciation/ Amortization
- 30.28
- Other Operating Expenses Total
- 51.88
- Total Operating Expense
- 1099.83
- Operating Income
- 88.23
- Net Income Before Taxes
- 98.51
- Net Income
- 97.09
- Diluted Normalized EPS
- 2.15
- Period
- 2021
- Total Assets
- 858.15
- Total Liabilities
- 433.4
- Total Equity
- 424.75
- Tangible Book Valueper Share Common Eq
- 7.33
- Period
- 2021
- Cashfrom Operating Activities
- 50.83
- Cashfrom Investing Activities
- -70.35
- Cashfrom Financing Activities
- 47.27
- Net Changein Cash
- 27.75
- Period
- 2020
- Total Revenue
- 853.07
- Selling/ General/ Admin Expenses Total
- 188.56
- Depreciation/ Amortization
- 36.91
- Other Operating Expenses Total
- 31.5
- Total Operating Expense
- 821.46
- Operating Income
- 31.61
- Net Income Before Taxes
- 39.11
- Net Income
- 33.58
- Diluted Normalized EPS
- 0.75
- Period
- 2020
- Total Assets
- 663.46
- Total Liabilities
- 379.4
- Total Equity
- 284.06
- Tangible Book Valueper Share Common Eq
- 4.49
- Period
- 2020
- Cashfrom Operating Activities
- 11.02
- Cashfrom Investing Activities
- -12.46
- Cashfrom Financing Activities
- 5.49
- Net Changein Cash
- 4.04
- Period
- 2019
- Total Revenue
- 768.54
- Selling/ General/ Admin Expenses Total
- 168.3
- Depreciation/ Amortization
- 39.9
- Other Operating Expenses Total
- 32.9
- Total Operating Expense
- 740.92
- Operating Income
- 27.61
- Net Income Before Taxes
- 29.18
- Net Income
- 28.85
- Diluted Normalized EPS
- 0.64
- Period
- 2019
- Total Assets
- 615.18
- Total Liabilities
- 362.08
- Total Equity
- 253.09
- Tangible Book Valueper Share Common Eq
- 3.65
- Period
- 2019
- Cashfrom Operating Activities
- 17.37
- Cashfrom Investing Activities
- -13.05
- Cashfrom Financing Activities
- -0.44
- Net Changein Cash
- 3.88
- Period
- 2025-03-31
- Total Revenue
- 465.85
- Selling/ General/ Admin Expenses Total
- 81.56
- Depreciation/ Amortization
- 16.47
- Other Operating Expenses Total
- 26.3
- Total Operating Expense
- 440.08
- Operating Income
- 25.77
- Net Income Before Taxes
- 25.71
- Net Income
- 20.32
- Diluted Normalized EPS
- 0.35
- Period
- 2025-03-31
- Total Assets
- 1778.1
- Total Liabilities
- 621.87
- Total Equity
- 1156.23
- Tangible Book Valueper Share Common Eq
- 18.43
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 32.06
- Cashfrom Investing Activities
- -321.51
- Cashfrom Financing Activities
- 299.89
- Net Changein Cash
- 10.44
- Period
- 2024-12-31
- Total Revenue
- 452.78
- Selling/ General/ Admin Expenses Total
- 88.91
- Depreciation/ Amortization
- 4.93
- Other Operating Expenses Total
- 37.08
- Total Operating Expense
- 421.57
- Operating Income
- 31.21
- Net Income Before Taxes
- 35.21
- Net Income
- 26.69
- Diluted Normalized EPS
- 0.49
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 437.73
- Selling/ General/ Admin Expenses Total
- 92.06
- Depreciation/ Amortization
- 1.86
- Other Operating Expenses Total
- 31.5
- Total Operating Expense
- 395.51
- Operating Income
- 42.21
- Net Income Before Taxes
- 46.02
- Net Income
- 34.85
- Diluted Normalized EPS
- 0.65
- Period
- 2024-09-30
- Total Assets
- 1562.25
- Total Liabilities
- 451.82
- Total Equity
- 1110.43
- Tangible Book Valueper Share Common Eq
- 18.37
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 12.43
- Cashfrom Investing Activities
- -203.74
- Cashfrom Financing Activities
- 193.91
- Net Changein Cash
- 2.6
- Period
- 2024-06-30
- Total Revenue
- 455.22
- Selling/ General/ Admin Expenses Total
- 92.25
- Depreciation/ Amortization
- 5.73
- Other Operating Expenses Total
- 28.54
- Total Operating Expense
- 409.32
- Operating Income
- 45.89
- Net Income Before Taxes
- 48.17
- Net Income
- 36.17
- Diluted Normalized EPS
- 0.71
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 423.07
- Selling/ General/ Admin Expenses Total
- 64.79
- Depreciation/ Amortization
- 9.62
- Other Operating Expenses Total
- 53.38
- Total Operating Expense
- 384.32
- Operating Income
- 38.76
- Net Income Before Taxes
- 42.2
- Net Income
- 28.28
- Diluted Normalized EPS
- 0.55
- Period
- 2024-03-31
- Total Assets
- 1293.21
- Total Liabilities
- 445.98
- Total Equity
- 847.23
- Tangible Book Valueper Share Common Eq
- 14.73
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 73.37
- Cashfrom Investing Activities
- -83.3
- Cashfrom Financing Activities
- 5.2
- Net Changein Cash
- -4.72
- Period
- 2023-12-31
- Total Revenue
- 444.55
- Selling/ General/ Admin Expenses Total
- 92.71
- Depreciation/ Amortization
- 8.45
- Other Operating Expenses Total
- 29.24
- Total Operating Expense
- 402.43
- Operating Income
- 42.12
- Net Income Before Taxes
- 44.02
- Net Income
- 31.99
- Diluted Normalized EPS
- 0.63
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Morepen Laboratories Technical
Moving Average
SMA
- 5 Day61.63
- 10 Day62.95
- 20 Day63.98
- 50 Day61.66
- 100 Day56.81
- 300 Day68.99
Morepen Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Orchid Pharma
- 708.95
- 5.65
- 0.8
- 1998
- 603.8
- 3599.82
- Gufic Biosciences
- 351
- -1.25
- -0.35
- 501.1
- 285
- 3519.75
- Morepen Laboratories
- 62.76
- 0.45
- 0.72
- 100.8
- 41.66
- 3438.96
- Alembic
- 115.3
- 0.9
- 0.79
- 169
- 85.55
- 2951.66
- Solara Active Pharma Sciences
- 617.35
- -1.75
- -0.28
- 885.95
- 441.1
- 2972.72
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Orchid Pharma
- 35.8
- 2.82
- 2.14
- 2.75
- Gufic Biosciences
- 50.52
- 5.86
- 22.25
- 10.48
- Morepen Laboratories
- 28.59
- 2.98
- 13.59
- 5.91
- Alembic
- 9.51
- 1.26
- 12.21
- 63.51
- Solara Active Pharma Sciences
- 4538.57
- 2.79
- -6.41
- -6.17
Morepen Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 12-May-25
- Audited Results & Final Dividend
- 06-Feb-25
- Quarterly Results
- 11-Nov-24
- Quarterly Results
- 12-Aug-24
- Quarterly Results
- 21-May-24
- Audited Results
- 31-Jan-24
- Quarterly Results
- 02-Nov-23
- Quarterly Results
- 05-Aug-23
- Quarterly Results
- 16-May-23
- Audited Results
- 13-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 10-Feb-25
- 17-Jan-25
- EGM
- 28-Sept-24
- 11-Sept-24
- AGM
- 18-Mar-24
- 26-Feb-24
- EGM
- 28-Sept-23
- 05-Sept-23
- AGM
- 05-Mar-22
- 11-Feb-22
- EGM
- 20-May-21
- 28-Apr-21
- EGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-May-25
- -
- -
- 0.2


